Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (31)

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  2. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  3. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. Prenatal air pollution exposure and growth and cardio-metabolic risk in preschoolers

    Environment International, Vol. 138

  2. Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data

    Leukemia Research, Vol. 95

2019

  1. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

  2. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155

  3. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

  4. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

    Cancers, Vol. 11, Núm. 11

  5. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2017

  1. Chronic opioid therapy in long-term cancer survivors

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 236-250

  2. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

  3. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance

    American Journal of Hematology

2016

  1. Assessing the role of TUBA4A gene in frontotemporal degeneration

    Neurobiology of Aging, Vol. 38, pp. 215.e13-215.e14

  2. Lamin A is involved in the development of vascular calcification induced by chronic kidney failure and phosphorus load

    Bone, Vol. 84, pp. 160-168

2015

  1. Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain

    Brain

  2. Convergent genetic and expression data implicate immunity in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 11, Núm. 6, pp. 658-671